Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $341.00

Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price objective raised by Barclays from $329.00 to $341.00 in a report issued on Monday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

A number of other equities research analysts also recently weighed in on ASND. Wall Street Zen raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Sunday, November 8th. Morgan Stanley dropped their price objective on shares of Ascendis Pharma A/S from $275.00 to $273.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 1st. Wedbush reissued an “outperform” rating and issued a $327.00 target price on shares of Ascendis Pharma A/S in a report on Tuesday, September 1st. Stifel Nicolaus decreased their target price on Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Finally, Citigroup decreased their target price on Ascendis Pharma A/S from $360.00 to $330.00 and set a “buy” rating for the company in a research note on Monday, October 26th. Nineteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Ascendis Pharma A/S has a consensus rating of “Moderate Buy” and a consensus price target of $312.67.

Get Our Latest Stock Report on Ascendis Pharma A/S

Ascendis Pharma A/S Stock Performance

Shares of ASND opened at $270.33 on Monday. The business’s fifty day moving average price is $242.90 and its 200 day moving average price is $240.53. Ascendis Pharma A/S has a 12-month low of $188.08 and a 12-month high of $282.15. The stock has a market capitalization of $16.86 billion, a PE ratio of 17.67 and a beta of 0.40. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.89 and a quick ratio of 2.29.

Insider Buying and Selling at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, EVP Anni Lotte Kirstine S. Pedersen sold 20,000 shares of the firm’s stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $263.89, for a total value of $5,277,800.00. Following the sale, the executive vice president directly owned 19,460 shares in the company, valued at approximately $5,135,299.40. This trade represents a 50.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Mads Bodenhoff sold 3,000 shares of the firm’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the sale, the senior vice president owned 3,000 shares in the company, valued at $810,570. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 40.00% of the stock is owned by company insiders.

Institutional Trading of Ascendis Pharma A/S

A number of large investors have recently modified their holdings of ASND. Integrated Wealth Concepts LLC boosted its stake in Ascendis Pharma A/S by 6.8% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 1,520 shares of the biotechnology company’s stock valued at $346,000 after purchasing an additional 97 shares during the period. Castleark Management LLC grew its position in Ascendis Pharma A/S by 42.8% in the 3rd quarter. Castleark Management LLC now owns 88,132 shares of the biotechnology company’s stock worth $20,079,000 after purchasing an additional 26,436 shares during the last quarter. Allworth Financial LP increased its stake in shares of Ascendis Pharma A/S by 132.5% in the third quarter. Allworth Financial LP now owns 558 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 318 shares during the period. Progeny 3 Inc. acquired a new stake in shares of Ascendis Pharma A/S in the third quarter valued at approximately $1,192,000. Finally, Inspire Advisors LLC acquired a new stake in shares of Ascendis Pharma A/S in the third quarter valued at approximately $268,000.

Ascendis Pharma A/S Company Profile

(Get Free Report)

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.

Further Reading

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.